Results 31 to 40 of about 30,003 (256)

Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens

Frontiers in Immunology, 2020
Patients undergoing allogeneic stem cell transplantation as treatment for hematological diseases face the risk of Graft-versus-Host Disease as well as relapse. Graft-versus-Host Disease and the favorable Graft-versus-Leukemia effect are mediated by donor
Kyra J. Fuchs, M. Willy Honders, Edith D. van der Meijden, Edith D. van der Meijden, Alwin E. Adriaans, Dyantha I. van der Lee, Margot J. Pont, Margot J. Pont, Ramin Monajemi, Szymon M. Kielbasa, Peter A. C. ’t Hoen, Peter A. C. ’t Hoen, Cornelis A. M. van Bergen, J. H. Frederik Falkenburg, Marieke Griffioen   +14 more
doaj   +1 more source

The Genomic Landscape of Antigenic Targets for T Cell-Based Leukemia Immunotherapy

Frontiers in Immunology, 2019
Intensive fundamental and clinical research in cancer immunotherapy has led to the emergence and evolution of two parallel universes with surprisingly little interactions: the realm of hematologic malignancies and that of solid tumors.
Marie-Pierre Hardy, Krystel Vincent, Claude Perreault   +2 more
doaj   +1 more source

A Review of Cyclophosphamide-Induced Transplantation Tolerance in Mice and Its Relationship With the HLA-Haploidentical Bone Marrow Transplantation/Post-Transplantation Cyclophosphamide Platform

Frontiers in Immunology, 2021
The bone marrow transplantation (BMT) between haplo-identical combinations (haploBMT) could cause unacceptable bone marrow graft rejection and graft-versus-host disease (GVHD).
Hisanori Mayumi
doaj   +1 more source

T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect

Nature Communications, 2020
In hematopoietic stem cell transplants, T cells mediate graft-versus-leukemia (GVL), but GVL can fail leading to leukemia relapse. Here the authors use a mouse model in which T cells target the minor histocompatibility antigen H60 to show how this can ...
Meng Zhou, Faruk Sacirbegovic, Kai Zhao, Sarah Rosenberger, Warren D. Shlomchik   +4 more
doaj   +1 more source

Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease

Frontiers in Immunology, 2022
Hematopoietic allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with hematological malignancies. However, due to disparities in major and minor histocompatibility antigens between donor and recipient, severe inflammatory ...
Matteo Doglio, Rachel E. Crossland, Ana C. Alho, Ana C. Alho, Olaf Penack, Anne M. Dickinson, Anne M. Dickinson, Georg Stary, Georg Stary, Georg Stary, João F. Lacerda, João F. Lacerda, Günther Eissner, Marit Inngjerdingen   +13 more
doaj   +1 more source

Antigen - presentation by vascular endothelium : its role for CTL - mediated vascular injury [PDF]

, 2008
Background: EC express and present MHC class I restricted peptide antigens and due to the exposed position may be targeted by antigen-specific CTL. We wished to explore the type of vascular injury that is mediated by peptidespecific CTL in vivo when EC ...
Wang, Xueya
core   +1 more source

Post‐Translational Isoaspartate Promotes Amyloid Formation in β2‐Microglobulin

Angewandte Chemie, EarlyView.
Chemical synthesis of five β2‐microglobulin (β2m) variants reveals the structural impact of Asn deamidation. By introducing Asp or isoAsp at susceptible Asn‐Gly sequences, we demonstrate that isoAsp17 formation specifically accelerates amyloid fibril formation, highlighting its potential contribution to dialysis‐related amyloidosis.
Ryuji Kawakami, Toshiki Takei, Masatomo So, Toshifumi Takao, Yoshinori Taguchi, Hironobu Hojo   +5 more
wiley   +2 more sources

Targeting the Retinoid X Receptor Pathway Prevents and Ameliorates Murine Chronic Graft-Versus-Host Disease

Frontiers in Immunology, 2022
Most allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients receive peripheral blood stem cell grafts resulting in a 30%–70% incidence of chronic graft-versus-host disease (cGVHD), a major cause of mortality and morbidity in long-term ...
Govindarajan Thangavelu, Michael C. Zaiken, Fathima A. Mohamed, Ryan Flynn, Jing Du, Stephanie Y. Rhee, Megan J. Riddle, Ethan G. Aguilar, Angela Panoskaltsis-Mortari, Martin E. Sanders, Bruce R. Blazar   +10 more
doaj   +1 more source

Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application

Haematologica, 2008
Background Donor lymphocyte infusion is an effective form of adoptive immunotherapy for hematologic malignancies after allogeneic stem cell transplantation.
Marieke Griffioen, H.M. Esther van Egmond, Helen Barnby-Porritt, Menno A.W.G. van der Hoorn, Renate S. Hagedoorn, Michel G.D. Kester, Nikolai Schwabe, Roel Willemze, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk   +9 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source